CD79A and ocular melanoma: Our results indicate that the serum IgA N-glycan profile can serve as a disease-specific biomarker in APSCT patients, whereas changes in salivary IgA reflect its effect on local immunity, rendering it suitable for monitoring OM progression and therapy response.